Showing 1591-1600 of 2527 results for "".
- There's a New Pico in Town: Wontech's Picocare Scores FDA Nodhttps://modernaesthetics.com/news/theres-a-new-pico-in-town-wontechs-picocare-scores-fda-nod/2472218/The U.S. Food and Drug Administration (FDA) cleared WONTECH’s picosecond laser device for tattoo removal. PICOCARE removes tattoos in various colors in less time with 1064nm, 532nm, 595nm, and 660nm wavelengths and selectively removes pigment par
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://modernaesthetics.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De
- SkinPen Milestone Highlights Growth in Microneedling Demandhttps://modernaesthetics.com/news/skinpen-milestone-highlights-growth-in-microneedling-demand/2486459/Revance announced that it has distributed more than 1 million SkinPen treatment kits nationwide since January 2025, marking a milestone for the company’s microneedling portfolio. The achievement comes approximately 1 year after the launch of SkinPen Precision Elite, the latest iteration of the de
- AAD 2026: Allergan Aesthetics Highlights TrenibotE Data and GLP-1 RA Patient Trendshttps://modernaesthetics.com/news/aad-2026-allergan-aesthetics-highlights-trenibote-data-and-glp-1-patient-trends/2486432/Allergan Aesthetics, an AbbVie company, presented four posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, including new findings on repeat treatment with investigational trenibotulinumtoxinE (TrenibotE) and insights into aesthetic trends among patients r
- AAD 2026: Lumenis Launches triLIFT 2.0 for Combined Muscle and Skin Rejuvenationhttps://modernaesthetics.com/news/lumenis-launches-trilift-20-for-combined-muscle-and-skin-rejuvenation/2486430/Lumenis Be Ltd. announced the commercial launch of triLIFT 2.0, a next-generation platform designed to deliver combined muscle stimulation and skin rejuvenation for facial and body applications. The system integrates Dynamic Muscle Stimulation technology (DMSt) with FibroBoost, aiming to address
- AAD 2026: CO2 Laser Resurfacing Linked to Transient Microbiome Shiftshttps://modernaesthetics.com/news/aad-2026-co2-laser-resurfacing-linked-to-transient-microbiome-shifts/2486399/New findings presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, provide insight into dynamic microbiome changes following ablative CO2 laser resurfacing and their relationship to wound healing. In this monocentric, double-blind, rando
- AAD 2026: Oral Supplement Shows Gains in Hair Strength, Collagen VIIhttps://modernaesthetics.com/news/aad-2026-oral-supplement-shows-gains-in-hair-strength-collagen-vii/2486396/New data presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, evaluated a nutraceutical approach to improving hair strength through collagen VII upregulation and mechanical resistance outcomes. The study assessed a daily oral supplement containing turmer
- FDA Clears Full-Wavelength Capability for Lasermach Laser Systemhttps://modernaesthetics.com/news/fda-clears-full-wavelength-capability-for-lasermach-laser-system/2486382/Wingderm announced that its Lasermach laser system has received expanded clearance from the US Food and Drug Administration (FDA), enabling use across all 3 wavelengths—755 nm, 808 nm, and 1064 nm. The update includes clearance for a mixed-wavelength handpiece combining all 3 wavelengths, as well
- Lynch Regenerative Medicine Expands PDGF Portfolio With GEM 21S® Distribution Agreementhttps://modernaesthetics.com/news/lynch-regenerative-medicine-expands-pdgf-portfolio-with-gem-21s-distribution-agreement/2486379/Lynch Regenerative Medicine, LLC (LRM) announced a definitive distribution agreement with Lynch Biologics, a Geistlich North America company, to commercialize GEM 21S®, an FDA-approved recombinant human platelet-derived growth factor (rhPDGF-BB) product, to licensed healthcare providers in the Un
- Revance, Teoxane Introduce RHA® Dynamic Volume for Facial Rejuvenationhttps://modernaesthetics.com/news/revance-teoxane-introduce-rha-dynamic-volume-for-facial-rejuvenation/2486353/Revance and Teoxane have announced the availability of RHA® Dynamic Volume, formerly known as RHA® 4 Mepi, expanding the RHA® Collection with a hyaluronic acid filler designed to adapt to facial movement and support natural-looking outcomes. The product has been approved by the US Food and Drug A